This is a correction to: Javier Muñoz, Shayna Sarosiek, Jorge J Castillo, Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies, The Oncologist, 2023, oyac260, https://doi.org/10.1093/oncolo/oyac260
In the originally published version of this manuscript, there was an error in the Summary, p7, third sentence should read “Clinical trials have also shown that some patients respond well to switching to other, next-generation, irreversible BTK inhibitors acalabrutinib or zanuibrutinib” instead of “Clinical trials have also shown that some patients respond well to switching to other, next-generation, irreversible BTK inhibitors acalabrutinib or ibrutinib.” This error has been corrected in the article.